Hiroko Nakayama1,2, Kanae Hata1, Izumi Matsuoka1, Liqing Zang1,2, Youngil Kim3, Djongchi Chu3, Lekh Raj Juneja3, Norihiro Nishimura1,2, Yasuhito Shimada2,4,5. 1. Graduate School of Regional Innovation Studies, Mie University, Tsu 514-8507, Japan. 2. Zebrafish Drug Screening Center, Mie University, Tsu 514-8507, Japan. 3. Rohto Pharmaceutical Co., Ltd, Osaka 544-0012, Japan. 4. Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan. 5. Department of Bioinformatics, Mie University Advanced Science Research Promotion Center, Tsu 514-8507, Japan.
Abstract
(1) Background: The obesity epidemic has been drastically progressing in both children and adults worldwide. Pharmacotherapy is considered necessary for its treatment. However, many anti-obesity drugs have been withdrawn from the market due to their adverse effects. Instead, natural products (NPs) have been studied as a source for drug discovery for obesity, with the goal of limiting the adverse effects. Zebrafish are ideal model animals for in vivo testing of anti-obesity NPs, and disease models of several types of obesity have been developed. However, the evidence for zebrafish as an anti-obesity drug screening model are still limited. (2) Methods: We performed anti-adipogenic testing using the juvenile zebrafish obesogenic test (ZOT) and mouse 3T3-L1 preadipocytes using the focused NP library containing 38 NPs and compared their results. (3) Results: Seven and eleven NPs reduced lipid accumulation in zebrafish visceral fat tissues and mouse adipocytes, respectively. Of these, five NPs suppressed lipid accumulation in both zebrafish and 3T3-L1 adipocytes. We confirmed that these five NPs (globin-digested peptides, green tea extract, red pepper extract, nobiletin, and Moringa leaf powder) exerted anti-obesity effects in diet-induced obese adult zebrafish. (4) Conclusions: ZOT using juvenile fish can be a high-throughput alternative to ZOT using adult zebrafish and can be applied for in vivo screening to discover novel therapeutics for visceral obesity and potentially also other disorders.
(1) Background: The obesity epidemic has been drastically progressing in both children and adults worldwide. Pharmacotherapy is considered necessary for its treatment. However, many anti-obesity drugs have been withdrawn from the market due to their adverse effects. Instead, natural products (NPs) have been studied as a source for drug discovery for obesity, with the goal of limiting the adverse effects. Zebrafish are ideal model animals for in vivo testing of anti-obesity NPs, and disease models of several types of obesity have been developed. However, the evidence for zebrafish as an anti-obesity drug screening model are still limited. (2) Methods: We performed anti-adipogenic testing using the juvenile zebrafish obesogenic test (ZOT) and mouse 3T3-L1 preadipocytes using the focused NP library containing 38 NPs and compared their results. (3) Results: Seven and eleven NPs reduced lipid accumulation in zebrafish visceral fat tissues and mouse adipocytes, respectively. Of these, five NPs suppressed lipid accumulation in both zebrafish and 3T3-L1 adipocytes. We confirmed that these five NPs (globin-digested peptides, green tea extract, red pepper extract, nobiletin, and Moringa leaf powder) exerted anti-obesity effects in diet-induced obese adult zebrafish. (4) Conclusions: ZOT using juvenile fish can be a high-throughput alternative to ZOT using adult zebrafish and can be applied for in vivo screening to discover novel therapeutics for visceral obesity and potentially also other disorders.
Entities:
Keywords:
diabetes; drug discovery; metabolic syndrome; screening
Authors: Young-Je Kim; Myung-Sook Choi; Je Tae Woo; Mi Ji Jeong; Sang Ryong Kim; Un Ju Jung Journal: Mol Nutr Food Res Date: 2017-03-02 Impact factor: 5.914
Authors: W Timothy Garvey; Jeffrey I Mechanick; Elise M Brett; Alan J Garber; Daniel L Hurley; Ania M Jastreboff; Karl Nadolsky; Rachel Pessah-Pollack; Raymond Plodkowski Journal: Endocr Pract Date: 2016-05-24 Impact factor: 3.443